Hints and tips:
...including Alex Gourley, former co-chief operating officer at Walgreens Boots Alliance, Linda Wilding, a former private equity executive, and Annalisa Jenkins, former president and chief executive of Dimension Therapeutics...
...The partnership was set up to discover therapeutic antibodies. One success was Dupixent, which treats allergic diseases such as eczema and asthma....
...Sanofi said it would pay $11.6bn for the haemophilia specialist Bioverativ, a 63 per cent premium, while Celgene agreed to pay $9bn for Juno Therapeutics, a cellular therapy company — almost two times as...
...Amgen, the big US biotech group, in January agreed an R&D collaboration worth up to $585m with Kite Pharma, a Californian company that, together with Seattle-based Juno Therapeutics, is vying with Novartis...
...In terms of therapeutic gases, Linde is currently second to Air Liquide, with just over $1bn last year. Here’s a slide from a recent presentation setting out Linde’s thinking....
...“If demand is weak in one sector we invariably find it is holding up reasonably robustly elsewhere.”...
...- ARM Holdings expects 20011 sales will be at least in line with current market expectations — statement....
...Yet even after France’s regional health insurance groups stopped reimbursing the drug after concluding it had no therapeutic value, it remained authorised for use in the country until late 2009 – shortly...
...Grifols, which is still part-owned and run by the Grifols founding family in Spain, said the deal would create one of the world’s leading suppliers of plasma protein therapeutics products....
...Binding Site Group Bio Products Laboratory (BPL) The Book Depository Brompton Bicycle Bupa International CarnaudMetalbox Engineering Centrax Chelton Alfred Cheyne Engineering ContiTech Beattie Controlled Therapeutics...
...Cell Therapeutics, a Seattle-based cancer drug specialist, was one of the top risers in the small-cap Russell 2000 index, climbing 28.4 per cent to $1.15....
...French biotech company ExonHit Therapeutics declined 13.7 per cent to €4.1 after the company launched a €15.6m capital increase of shares priced at €3.75....
...Novartis rose 1.8 per cent to SFr52.40 after signing a drug discovery deal with British biotechnology company Heptares Therapeutics that could be worth up to $200m....
...With three large-scale deals unveiled in less than two months totalling about $150bn – casting into obscurity a series of smaller deals such as Gilead’s $1.4bn bid Thursday for CV Therapeutics -– the pace...
...The company said it “believes that Acomplia will remain an important therapeutic answer to a highly prevalent and increasing unmet medical need”, and pledged to continue studies on its use for patients with...
...United Therapeutics rose 33 per cent to $91....
...However, some traders cast doubt on the renewed bid talk, saying Actelion’s share price could be buffeted by the release today of a clinical trial from United Therapeutics, a US rival....
...Genmab, which discovers and develops human antibodies for the treatment of life-threatening and debilitating diseases, has been linked with GlaxoSmithKline, while Silence Therapeutics could make a good technology...
...Merck of the US last year partnered Advinus Therapeutics, a local company backed by Tata, one of India’s largest conglomerates....
...Ravi Mehrotra at CSFB said there was a “large unmet therapeutic need for effective HAe treatments.”...
International Edition